Citations

Clear

17 citation(s) found for "Bull, Todd".

Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2)
Al‐Naamani, Nadine , Krowka, Michael J. , Forde, Kimberly A. , Feng, Rui , Dweik, Raed A. , Bartolome, Sonja, Bull, Todd , Patel, Mamta, Oh, Jae K. , Lin, Grace , Doyle, Margaret F. , Denver, Nina, Andrew, Ruth , Fallon, Michael B. , Group, , for the Pulmonary Vascular Complications of Liver Disease Study, Al-Naamani, Nadine , Krok, Karen , Feng, Rui, Heresi, Gustavo A. , Roberts, Kari E. , Austin, Eric , Hemnes, Anna R. , MacLean, Margaret R. , Kawut, Steven M. , Group, , for the Pulmonary Vascular Complications of Liver Disease Study

Mayo Clinic

Hepatology | May 14, 2020 | Volume: 73 | Issue: 2 | Pages: 726-737

10.1002/hep.31314 | PMID 32407592 Get It

Background and Aims Portopulmonary hypertension (POPH) was previously associated with a single‐nucleotide polymorphism (SNP) rs7175922 in aromatase (cytochrome P450 family 19 subfamily A member 1 [CYP19A1]). We sought to determine whether genetic variants and metabolites in the estrogen signaling pathway are associated with POPH. Approach and Results We performed a multicenter case‐control study. POPH patients had mean pulmonary artery pressure >25 mm Hg, pulmonary vascular resistance >240 dyn‐sec/cm−5, and pulmonary artery wedge pressure ≤15 mm Hg without another cause of pulmonary hypertension. Controls had advanced liver disease, right ventricular (RV) systolic pressure <40 mm Hg, and normal RV function by echocardiography. We genotyped three SNPs in CYP19A1 and CYP1B1 using TaqMan and imputed SNPs in estrogen receptor 1 using genome‐wide markers. Estrogen metabolites were measured in blood and urine samples. There were 37 patients with POPH and 290 controls. Mean age was 57 years, and 36% were female. The risk allele A in rs7175922 (CYP19A1) was significantly associated with higher levels of estradiol (P = 0.02) and an increased risk of POPH (odds ratio [OR], 2.36; 95% confidence interval [CI], 1.12‐4.91; P = 0.02) whereas other SNPs were not. Lower urinary 2‐hydroxyestrogen/16‐α‐hydroxyestrone (OR per 1‐ln decrease = 2.04; 95% CI, 1.16‐3.57; P = 0.01), lower plasma levels of dehydroepiandrosterone‐sulfate (OR per 1‐ln decrease = 2.38; 95% CI, 1.56‐3.85; P < 0.001), and higher plasma levels of 16‐α‐hydroxyestradiol (OR per 1‐ln increase = 2.16; 95% CI, 1.61‐2.98; P < 0.001) were associated with POPH. Conclusions Genetic variation in aromatase and changes in estrogen metabolites were associated with POPH.
BMP9/10 in Pulmonary Vascular Complications of Liver Disease
Rochon, Elizabeth R. , Krowka, Michael J. , Bartolome, Sonja, Bull, Todd M., Forde, Kimberly A. , Patel, Mamta, Lin, Grace , McNeil, Megan , Al‐Naamani, Nadine , Roman, Beth L. , Yu, Paul B. , Fallon, Michael B. , Gladwin, Mark T. , Kawut, Steven M , Al-Naamani, Nadine , Heresi, Gustavo A. , Roberts, Kari E. , Hemnes, Anna R. , Krok, Karen , Kawut, Steven M.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | February 21, 2020 | Volume: 201 | Issue: 12 | Pages: 1575-1578

10.1164/rccm.201912-2514le | PMID 32083953 Get It

Estrogen Metabolism in Portopulmonary Hypertension (POPH): A Case-Control Study
Krowka, Michael J. , Forde, Kimberly A. , Bull, Todd M., Bartolome, Sonja, Lin, Grace , Oh, Jae K. , Mottram, Carl, Scanlon, Paul D., Patel, M., Fallon, Michael B. , Al‐Naamani, Nadine , Heresi, Gustavo A. , Roberts, Kari E. , Hemnes, Anna R. , Krok, Karen , DuBrock, Hilary M. , Austin, Eric , Kawut, Steven M.

Mayo Clinic

C52. USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5097-A5097

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5097 Get It

Self-Reported Pulmonary Hypertension (PH) Referral Trends Amongst U.S.-Based Physicians
Badesch, David B., Bull, Todd M., Lahm, Tim , Laughlin, A., Aune, Ragnhild E. , Brown, Laura Mae , Gray, Michael P. , DuBrock, Hilary M. , de Jesus Perez, Vinicio , Leary, Peter J. , Aune, R.

Mayo Clinic

C52. USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5090-A5090

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5090 Get It

Increasing Age Is Associated with Worsening Physical Function Despite More Favorable Cardiopulmonary Hemodynamics: A Pulmonary Hypertension Association Registry (PHAR) Report
Kime, Noah , Bartolome, Sonja, Badesch, David B., Bull, Todd M., Chakinala, Murali M. , Elwing, Jean , Feldman, Jeremy P., Fineman, Jeffrey R. , Grinnan, D. , Mathai, S.C. , McConnell, J.W. , Presberg, Kenneth W., Robinson, Jeffrey C. , Sager, Jeffrey S., Shlobin, Oksana A. , Zamanian, Roham T. , Marco, Teresa De , Investigators, PHAR, DesJardin, Jacqueline T. , Kolaitis, Nicholas A , Kronmal, Richard A. , Benza, Raymond L. , Rosenzweig, Erika B. , Burger, Charles D. , Horn, Evelyn M. , Lammi, Matthew R. , Simon, Marc A. , Thenappan, Thenappan

Mayo Clinic

A105. GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A2516-A2516

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2516 Get It

Enhancing Insights into Pulmonary Vascular Disease Through a Precision Medicine Approach. A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop Report
Newman, John H. , Rich, Stuart , Alexander, John H. , Beck, Gerald J. , Benza, Raymond L. , Bull, Todd M., Chun, Hyung J. , Doogan, Declan, Dupuis, Jocelyn , Erzurum, Serpil C. , Frantz, Robert P. , Geraci, Mark W. , Gillies, Hunter , Gladwin, Mark T. , Gray, Michael P. , Hill, Nicholas S. , Hunter, Kendall S. , Jing, Zhi‐Cheng , Johns, Roger A. , Kaul, Sanjay , Lahm, Tim , Lewis, Greg , Mathai, Stephen C. , McLaughlin, Vallerie V. , Michelakis, Evangelos D. , Nathan, Steven D. , Nichols, William C. , Page, Grier P. , Rabinovitch, Marlene , Rich, Jonathan D. , Rischard, Franz , Rounds, Sharon , Shah, Sanjiv J. , Tapson, Victor F. , Lowy, Naomi, Stockbridge, Norman, Weinmann, Gail, Xiao, Lei , Xiao, Lei , Abman, Steven H. , Barnard, John , Benza, Raymond L. , Chan, Stephen Y. , Hemnes, Anna R. , Herbst, Roy S. , Hernandez, Adrian F. , Horn, Evelyn M. , Kawut, Steven M. , Leopold, Jane A. , McLaughlin, Vallerie V. , Shah, Sanjiv J , Frantz, Robert P , Rischard, Franz P , Mathai, Stephen C

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 21, 2017 | Volume: 195 | Issue: 12 | Pages: 1661-1670

10.1164/rccm.201701-0150ws | PMID 28430547 Get It

Abstract The Division of Lung Diseases of the NHLBI and the Cardiovascular Medical Education and Research Fund held a workshop to discuss how to leverage the anticipated scientific output from the recently launched “Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics” (PVDOMICS) program to develop newer approaches to pulmonary vascular disease. PVDOMICS is a collaborative, protocol-driven network to analyze all patient populations with pulmonary hypertension to define novel pulmonary vascular disease (PVD) phenotypes. Stakeholders, including basic, translational, and clinical investigators; clinicians; patient advocacy organizations; regulatory agencies; and pharmaceutical industry experts, joined to discuss the application of precision medicine to PVD clinical trials. Recommendations were generated for discussion of research priorities in line with NHLBI Strategic Vision Goals that include: (1) A national effort, involving all the stakeholders, should seek to coordinate biosamples and biodata from all funded programs to a web-based repository so that information can be shared and correlated with other research projects. Example programs sponsored by NHLBI include PVDOMICS, Pulmonary Hypertension Breakthrough Initiative, the National Biological Sample and Data Repository for PAH, and the National Precision Medicine Initiative. (2) A task force to develop a master clinical trials protocol for PVD to apply precision medicine principles to future clinical trials. Specific features include: (a) adoption of smaller clinical trials that incorporate biomarker-guided enrichment strategies, using adaptive and innovative statistical designs; and (b) development of newer endpoints that reflect well-defined and clinically meaningful changes. (3) Development of updated and systematic variables in imaging, hemodynamic, cellular, genomic, and metabolic tests that will help precisely identify individual and shared features of PVD and serve as the basis of novel phenotypes for therapeutic interventions.